Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT05898464
PHASE4
Immunogenicity and Safety of Recombinant Zoster Vaccine in People Living With HIV
Sponsor: Seoul National University Hospital
View on ClinicalTrials.gov
Summary
The purpose of this study is to compare the immunogenicity and safety of recombinant zoster vaccine according to CD4+ T-cell count and age in people living with HIV, and to provide evidence to guide immunization of people living with HIV.
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2023-06-27
Completion Date
2026-03-31
Last Updated
2025-10-02
Healthy Volunteers
No
Interventions
BIOLOGICAL
Recombinant zoster vaccination
Two doses of recombinant zoster vaccine(Shingrix®), 2 months apart
Locations (2)
Seoul National University Hospital
Seoul, South Korea
National Medical Center
Seoul, South Korea